Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug;11(4):477-485.
doi: 10.1007/s11764-017-0606-3. Epub 2017 Feb 22.

A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy

Affiliations
Randomized Controlled Trial

A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy

Pragati Advani et al. J Cancer Surviv. 2017 Aug.

Abstract

Purpose: A randomized pilot trial evaluated the hypothesis that early intervention lessens sexual dysfunction in the first year on aromatase inhibitors. A secondary aim was comparing the efficacy of two vaginal moisturizers.

Methods: Fifty-seven postmenopausal women with early stage breast cancer starting aromatase inhibitors were randomized to three treatment groups. All received a handout on managing sexual and other side effects. The Usual Care group received no additional therapy. The Active Treatment groups received a 6-month supply of a vaginal moisturizer (hyaluronic acid-based in Active Group-H and prebiotic in Active Group-P) and a vaginal lubricant and dilator, plus access to an educational website and phone coaching. Questionnaires completed at baseline, 6, and 12 months included the Female Sexual Function Index (FSFI), Menopausal Sexual Interest Questionnaire (MSIQ), Female Sexual Distress Scale-Revised (FSDS-R), and a menopausal symptom scale.

Results: Forty-nine women (86%) provided follow-up data. Mean age was 59 and 77% were non-Hispanic Caucasian. Sexual function was impaired at baseline, but remained stable over 12 months for all groups. The combined active treatment group had less dyspareunia (P = 0.07) and sexual distress (P = 0.02) at 6 months than the Usual Care group. At 6 months, the Active-H group improved significantly more than the Active-P group on FSFI total score (P = 0.04).

Conclusions: Sexual counseling helped women maintain stable sexual function on aromatase inhibitors. Active intervention resulted in better outcomes at 6 months.

Implications for cancer survivors: This promising pilot trial suggests a need for more research on preventive counseling to maintain sexual function during aromatase inhibitor treatment.

Keywords: Aromatase inhibitors; Breast cancer; Dyspareunia; Genitourinary atrophy; Prevention; Sexual dysfunction.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet Oncol. 2015 Jul;16(7):848-58 - PubMed
    1. J Gerontol B Psychol Sci Soc Sci. 2009 Nov;64 Suppl 1:i106-18 - PubMed
    1. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):549-59 - PubMed
    1. Dan Med Bull. 2010 Sep;57(9):B4184 - PubMed
    1. Clin Breast Cancer. 2015 Dec;15(6):527-535.e2 - PubMed

Publication types

Substances

LinkOut - more resources